New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options
June 15 2023 - 7:00AM
TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical
technology company focused on providing innovative soft-tissue
reconstruction solutions that optimize clinical outcomes by
prioritizing the preservation and restoration of the patient's own
anatomy, today announced results from a consumer survey on consumer
awareness, preferences, and doctor expectations regarding hernia
repair options.
The survey, which was conducted in May 2023, included 1,152
consumers and found a significant preference for more natural
hernia repair options, particularly among those who have previously
had a repair using permanent synthetic mesh. The majority of
respondents also expressed a reliance on primary care physicians
and healthcare professionals for guidance, emphasizing the
importance of shared decision-making.
Highlights from the survey include:
Consumers Are Concerned About Permanent Synthetic
Mesh
- 77.1% of consumers who had a permanent plastic mesh repair
would prefer a more natural repair option for subsequent hernias
requiring surgery.
- 57% of consumers without a hernia expressed a preference for a
more natural repair option due to concerns about permanent plastic
materials in their bodies.
There Is a High Desire for Shared
Decision-Making
- 86.6% of all respondents believe in shared decision-making with
their doctor, and 69.8% trust that their medical provider will
educate them on all available options.
- 79.2% of consumers stated they would seek alternative options
if their doctor or hospital did not offer a natural repair
option.
Consumers Expect Most Advanced and Innovative
Solutions
- 94.7% of all respondents considered it important or very
important for their doctor or surgeon to be current with the top
innovations in medical care.
- 72.0% of respondents who have had a hernia repair expected
their surgeon to use the most innovative and advanced
materials.
- 82% of consumers who have not had a hernia expected their
surgeon to be aware of and use the most advanced hernia repair
materials available.
“The results of this survey support TELA Bio’s mission and the
core design principles of OviTex® Reinforced Tissue Matrix,” said
Paul Talmo, Chief Strategic Officer at TELA Bio. “In observance of
Hernia Awareness Month, these survey findings demonstrate consumer
desire for more natural repair options as well as the opportunity
to have a stronger voice in their healthcare decisions. While
permanent synthetic mesh is still used for most hernia repairs,
many surgeons are also looking for advancements that provide
durability while reducing the amount of permanent foreign
bodies.”
About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:
TELA) is a commercial-stage medical technology company focused on
providing innovative technologies that optimize clinical outcomes
by prioritizing the preservation and restoration of the patient's
own anatomy. The Company is committed to providing surgeons with
advanced, economically effective soft-tissue reconstruction
solutions that leverage the patient's natural healing response
while minimizing long-term exposure to permanent synthetic
materials. For more information, visit www.telabio.com.
About OviTex OviTex Reinforced Tissue
Matrix is intended for use as a surgical mesh to reinforce and/or
repair soft tissue where weakness exists. Indications for use
include the repair of hernias and/or abdominal wall defects that
require the use of reinforcing or bridging material to obtain the
desired surgical outcome. Do not use OviTex in patients known to be
sensitive to materials of ovine (sheep) origin. For prescription
use only. For additional important safety information, please see
the OviTex Reinforced Tissue Matrix Instructions for Use.
Caution Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations are forward-looking statements and reflect the current
beliefs of TELA Bio's management. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements. These risks and uncertainties are
described more fully in the "Risk Factors" section and elsewhere in
our filings with the Securities and Exchange Commission and
available at www.sec.gov, including in our Annual Report on Form
10-K and Quarterly Reports on Form 10-Q. Any forward-looking
statements that we make in this announcement speak only as of the
date of this press release, and TELA Bio assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise after the date of this
press release, except as required under applicable law.
Investor ContactGreg
Chodaczek347-620-7010ir@telabio.com
Media ContactAlyson
Kuritz908-892-7149alyson@0to5.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Apr 2024 to May 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From May 2023 to May 2024